Pacific Biosciences Of California (PACB) Operating Expenses (2016 - 2026)
Pacific Biosciences Of California has reported Operating Expenses over the past 16 years, most recently at $57.8 million for Q4 2025.
- For Q4 2025, Operating Expenses fell 64.58% year-over-year to $57.8 million; the TTM value through Dec 2025 reached $599.6 million, up 17.21%, while the annual FY2025 figure was $599.6 million, 17.21% up from the prior year.
- Operating Expenses for Q4 2025 was $57.8 million at Pacific Biosciences Of California, up from $54.8 million in the prior quarter.
- Over five years, Operating Expenses peaked at $427.6 million in Q1 2025 and troughed at $12.0 million in Q3 2021.
- A 5-year average of $102.3 million and a median of $88.4 million in 2022 define the central range for Operating Expenses.
- Biggest five-year swings in Operating Expenses: skyrocketed 634.72% in 2022 and later crashed 67.25% in 2025.
- Year by year, Operating Expenses stood at $81.4 million in 2021, then grew by 13.24% to $92.2 million in 2022, then grew by 5.31% to $97.1 million in 2023, then soared by 67.92% to $163.1 million in 2024, then crashed by 64.58% to $57.8 million in 2025.
- Business Quant data shows Operating Expenses for PACB at $57.8 million in Q4 2025, $54.8 million in Q3 2025, and $59.5 million in Q2 2025.